CAS 252049-06-2 - China Manufacturers, Factory, Suppliers

CAS 252049-06-2, , , ,. The product will supply to all over the world, such as Europe, America, Australia,, ,, .

Related Products

Fmoc-N-Me-Thr-OH CAS 252049-06-2 Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — Fmoc-N-Me-Thr-OH CAS 252049-06-2 Fmoc-N-Methyl-L-Threonine Purity >99.0% (HPLC)
Read More

Fmoc-N-Me-Thr-OH CAS 252049-06-2 Fmoc-N-Methyl-L-Threonine Purity >99.0% (HPLC)

Z-HomoPhe-OH CAS 127862-89-9 Assay ≥98.0% (HPLC)

Z-Ser-OH CAS 1145-80-8 N-Cbz-L-Serine Assay ≥99.0% (HPLC)

Z-Hyp-OH CAS 13504-85-3 Purity ≥99.0% (HPLC)

N-Cbz-N-Methyl-L-Isoleucine CAS 42417-66-3 Purity ≥98.0% (HPLC)

D-2-Cyanophenylalanine CAS 263396-41-4 Assay ≥98.0% (HPLC)

Top Selling Products

Related Blog
Reviews

Paxlovid: what we know about Pfizer's Covid-19 pill

Pfizer is seeking emergency use authorisation from the FDA for its novel Covid-19 antiviral pill Paxlovid. Share Article On the heels of Merck antiviral molnupiravir’s UK approval, Pfizer...
Xi presents award to top scientists

President Xi Jinping, also general secretary of the Communist Party of China (CPC) Central Committee and chairman of the Central Military Commission, presents China’s top science award to a...
The “Summit on COVID-19 Diagnostics & Treatment”

The “Summit on COVID-19 Diagnostics & Treatment” September 27-29, 2021 at China International Exhibition Center (Tianzhu New Hall), Beijing. The outbreak of Corona Virus Disease 2019 (...
Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study

Friday, November 05, 2021 – 06:45am PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adult...
New COVID treatments offer hope

Scientists around the world have made promising breakthroughs in developing a cure for COVID-19. Among new developments include antiviral pills and antibody compounds. As more countries look to ado...
The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021

The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021 As the world’s second largest medical market, ...

2022.10.15 08:00:24
2022.06.27 11:45:36
2022.05.04 16:08:56
2022.03.02 02:07:56
2021.12.14 05:31:04
2021.11.13 00:18:31

CAS 252049-06-2 - China Manufacturers, Factory, Suppliers

Related Products

Fmoc-N-Me-Thr-OH CAS 252049-06-2 Fmoc-N-Methyl-L-Threonine Purity >99.0% (HPLC)

Fmoc-N-Me-Thr-OH CAS 252049-06-2 Fmoc-N-Methyl-L-Threonine Purity >99.0% (HPLC)

Z-HomoPhe-OH CAS 127862-89-9 Assay ≥98.0% (HPLC)

Z-Ser-OH CAS 1145-80-8 N-Cbz-L-Serine Assay ≥99.0% (HPLC)

Z-Hyp-OH CAS 13504-85-3 Purity ≥99.0% (HPLC)

N-Cbz-N-Methyl-L-Isoleucine CAS 42417-66-3 Purity ≥98.0% (HPLC)

D-2-Cyanophenylalanine CAS 263396-41-4 Assay ≥98.0% (HPLC)

Top Selling Products

Fmoc-3-Pal-OH CAS 175453-07-3 Assay ≥98.0% (HPLC)

Boc-Cys(pMeOBzl)-OH CAS 18942-46-6 Purity >98.0% (HPLC, TLC)

2-Thiophenethiol CAS 7774-74-5 Purity >97.0% (GC) Factory High Quality

2-Isopropylimidazole CAS 36947-68-9 Purity >99.0% (GC) Factory Hot Sale

D-(-)-Asparagine Monohydrate CAS 2058-58-4 H-D-Asn-OH·H2O Assay 99.0~101.0% (Titration)

N,N-Dimethylaniline (DMA) CAS 121-69-7 Purity >99.5% (GC) Factory

2-Aminobutanamide CAS 53726-14-0 Purity >98.0% (TLC)

2-Ethylphenylboronic Acid CAS 90002-36-1 Purity >99.5% (HPLC) Factory High Quality

N,N'-Di-tert-Butylcarbodiimide CAS 691-24-7 Purity >99.0% (GC)

(R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethanol CAS 127852-28-2 Purity >99.0% (GC) Aprepitant Intermediate

Mono-tert-Butyl Malonate CAS 40052-13-9 Purity >98.0% (Titration with NaOH) Factory

D-Asparagine Monohydrate CAS 5794-24-1 Assay ≥99.0% (HPLC) (Titration)

Paxlovid: what we know about Pfizer's Covid-19 pill

Xi presents award to top scientists

The “Summit on COVID-19 Diagnostics & Treatment”

Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study

New COVID treatments offer hope

The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021

2022.10.15 08:00:24

2022.06.27 11:45:36

2022.05.04 16:08:56

2022.03.02 02:07:56

2021.12.14 05:31:04

2021.11.13 00:18:31

related search